Mechanisms of Immunotoxicology in Cancer Patients

What this Trial Is About

Researchers are studying how cancer treatment with immune checkpoint inhibitors can lead to the development of autoimmunity. The goal is to understand the genetic and immune system factors that cause some cancer patients receiving checkpoint inhibitors to develop immune-related adverse events (irAEs). This observational study aims to enroll at least 300 patients who are prescribed checkpoint inhibitors to explore these effects in detail. Participants will provide blood and serum samples at enrollment and during scheduled times when receiving their cancer treatments and routine lab tests. Samples may also be collected if autoimmune symptoms develop. Urine samples may be collected as well. There are no planned treatment interventions in this study; it focuses on collecting biological samples and clinical data to analyze immune system changes and genetics related to treatment. During the study, researchers will collect clinical information from medical records and store coded data securely. They will analyze immune cell types and functions and track the occurrence of autoimmune side effects over six years. The study also aims to facilitate future research collaborations using the established databank of tissues and clinical data. Participants will be involved in providing samples and allowing review of their medical records during this time.

Autoimmunity After Checkpoint Blockade